secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coherus Oncology, Inc. (CHRS)
CIK:        0001512762
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001558370-25-010802
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coherus Q2 LOQTORZI rev $10M (+36% QoQ); UDENYCA divestiture closed for $483M
-----------------------------------------------------------------------------

- LOQTORZI net revenue $10.0M in Q2 2025, up 36% from $7.3M in Q1 2025 and $3.8M in Q2 2024.
- UDENYCA divestiture completed April 11, 2025; Coherus received $483.4M cash and is eligible for up to $75M milestones.
- Used proceeds to repay substantially all $230M of 2026 Convertible Notes and buy out royalty rights for $47.7M.
- Q2 2025 net loss from continuing ops $44.9M ($0.39 diluted loss) vs $54.9M ($0.48) YoY; non-GAAP net loss $39.0M.
- Cash, cash equivalents and marketable securities $238M at June 30, 2025; CHS-114 and casdozokitug data readouts expected 1H 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1512762/000155837025010802/0001558370-25-010802-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1512762/000155837025010802/chrs-20250807x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-010802

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer